Dihydromyricetin is a plant compound applied to skin as a serum that may gently reverse age-related changes in skin-cell genes and fight oxidative stress, inflammation, and sugar-driven damage. Early reports suggest smoother wrinkles and firmer, denser skin over about two months, with good tolerability — but the evidence is thin and unproven. Taken by mouth it likely does not reach skin. (Full Review)

Protocol

Form

Topical serum

Applied to clean, dry face and neck; best-evidenced route

Frequency

Twice daily

Morning and night; morning paired with broad-spectrum sunscreen

Titration

Start once daily

Evening for 1–2 weeks, then increase to twice daily if tolerated

Time to effect

Early changes

4 weeks

Some visible improvements already significant

Study endpoint

8 weeks

Biological age and visible changes measured

Typical course

1–2 months

Gradual results, not overnight

Benefits

Low: Epigenetic rejuvenation and improvement in visible signs of aging; antioxidant and anti-inflammatory skin support

Speculative: Skin brightening and anti-hyperpigmentation; anti-glycation and collagen preservation; anti-acne activity; wound healing and barrier repair support

Contraindications

Pregnancy or breastfeeding (oral)

Allergy to vine tea, Hovenia, or related flavonoids (both routes)

Alcohol-use disorder or chronic sedatives (high-dose oral)

Key Interactions

Sedative-hypnotics and benzodiazepines (diazepam, alprazolam), oral

Narrow-therapeutic-index CYP3A4 drugs (statins, calcineurin inhibitors), oral

Alcohol or antihistamine sleep aids (diphenhydramine), oral

GABA-active supplements (valerian, kava, magnesium glycinate), oral

Topical exfoliating acids (glycolic, salicylic)

Additive topical actives (vitamin C, niacinamide, tyrosinase inhibitors)

Retinoids (tretinoin) and in-office peels or lasers

Risk & Side Effects

Low: Gastrointestinal discomfort; skin irritation or sensitization

Speculative: Uncertain long-term effects of broad epigenetic modulation; additive sedation and altered alcohol handling

Monitoring

Marker	Target	Why
Biological skin age (epidermal DNA-methylation clock)	Lower than chronological age	Tracks the primary epigenetic mechanism directly
Dermal density / elasticity (ultrasound or cutometer)	Improvement vs. personal baseline	Objective structural readout of firmness and thickness
Hemoglobin A1c (HbA1c)	<5.4% (functional); conventional <5.7%	Reflects glycation load feeding the AGE–RAGE aging pathway
Fasting glucose	75–90 mg/dL (functional); conventional 70–99 mg/dL	Same glycation rationale, shorter-term
High-sensitivity C-reactive protein (hs-CRP)	<1.0 mg/L (functional); conventional <3.0 mg/L	Systemic inflammation that accelerates skin aging
Alanine aminotransferase / aspartate aminotransferase (ALT/AST)	ALT <25 U/L (men) / <20 U/L (women)	Only relevant with long-term high-dose oral use

Cadence: Skin parameters at 4 and 8 weeks, then every 3–6 months; optional bloodwork every 6–12 months

Qualitative Assessment

Smoother skin texture and reduced roughness on touch and in photos
Softer appearance of fine lines and periorbital wrinkles ("crow's feet")
Improved firmness and elasticity
Brighter, more even tone and radiance
Good tolerability — absence of persistent redness, stinging, or breakouts

Dihydromyricetin for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment